Drug intelligence / Profile preview

LTC002

Development stage: Preclinical
Lead developer: Beijing Zhidao Biological Technology
Modality: Recombinant Proteins and Enzymes

Overview

LTC002 is a protein analog of interleukin-2 (IL-2) featuring unique intramolecular disulfide bonds, developed by Leto Laboratories (Letolab). It functions as an agonist of the IL-2 receptor, designed to modulate immune responses by activating T-cells and natural killer (NK) cells for the treatment of solid tumors. In August, Letolab licensed the worldwide rights for the preclinical development, clinical research, and commercialization of LTC002 to TopAlliance (Junshi Biosciences) in a deal valued at over $150 million in total payments. The drug is currently in the IND-enabling/preclinical stage of development.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on LTC002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTC002.

Explore the full profile